Abstract
Objective: Rheumatic disease patients on certain immunomodulators are at increased risk of impaired humoral response to SARS-CoV-2 vaccines. We aimed to identify factors associated with breakthrough infection among patients with rheumatic diseases.
Methods: We identified patients with rheumatic diseases being treated with immunomodulators in a large healthcare system who received at least two doses of either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) vaccines or one dose of the Johnson & Johnson-Janssen (J&J) vaccine. We followed patients until SARS-CoV-2 infection, death, or December 15, 2021, when the Omicron variant became dominant in our region. We estimated the association of baseline characteristics with the risk of breakthrough infection using multivariable Cox regression.
Results: We analyzed 11,468 patients (75% female, mean age 60 years). Compared to antimalarial monotherapy, multiple immunomodulators were associated with higher risk of infection: anti-CD20 monoclonal antibodies (aHR 5.20), CTLA-4 Ig (aHR 3.52), mycophenolate (aHR 2.31), IL-6 inhibitors (aHR 2.15), JAK inhibitors (aHR 2.02), and TNF inhibitors (aHR 1.70). mRNA-1273 recipients had a lower risk of breakthrough infection compared to BNT162b2 recipients (aHR 0.66).
Conclusion: Among patients with rheumatic diseases, multiple immunomodulators were associated with increased risk of breakthrough infection, highlighting the need for additional mitigation strategies.
Introduction
Early in the COVID-19 pandemic, clinical research established that many medications used to treat systemic autoimmune rheumatic diseases (SARDs)—such as rheumatoid arthritis, lupus, and vasculitis—could blunt the body’s ability to produce antibodies following vaccination. However, a laboratory-observed "impaired humoral response" does not always translate directly to clinical vulnerability.
This study addresses a critical gap in the literature: identifying which specific clinical factors, ranging from drug classes to vaccine brands, actually increased the hazard of breakthrough infection in a real-world setting before the emergence of the Omicron variant.
Methods
Researchers conducted a retrospective cohort study using the Mass General Brigham (MGB) Electronic Health Record (EHR) data warehouse in Boston. This high-fidelity dataset integrated ICD-10 diagnosis codes, medication prescription records, and vaccination data linked to the Massachusetts state immunization registry.
Population and Follow-up
The study included 11,468 fully vaccinated adults with a SARD diagnosis who were prescribed immunomodulators. The "index date" for follow-up began 14 days after the final dose of the primary vaccine series. Patients were followed until they experienced a breakthrough infection (confirmed via PCR or antigen test), died, or reached the study cutoff of December 15, 2021.
Statistical Analysis
The team employed multivariable Cox regression to calculate adjusted Hazard Ratios (aHR), controlling for age, sex, smoking status, and comorbidities. Because patients often take multiple medications, a hierarchical system was used to assign each patient to a single primary medication category for analysis (e.g., prioritizing biologics over conventional synthetic DMARDs like methotrexate).
Results
During the pre-Omicron study period, 251 breakthrough infections occurred (an incidence rate of 2.6 per 1,000 person-months). The analysis revealed a clear "hierarchy of risk" regarding immunosuppressive therapies.
Medication-Specific Risk
Compared to patients on antimalarial monotherapy (the reference group), several drug classes were associated with a significantly higher risk of breakthrough infection:
- Anti-CD20 monoclonal antibodies (e.g., Rituximab): 5.20x higher risk (95% CI: 2.85, 9.48).
- CTLA-4 Ig (e.g., Abatacept): 3.52x higher risk (95% CI: 1.90, 6.51).
- Mycophenolate: 2.31x higher risk (95% CI: 1.25, 4.27).
- IL-6 inhibitors: 2.15x higher risk (95% CI: 1.09, 4.24).
- JAK inhibitors: 2.02x higher risk (95% CI: 1.01, 4.06).
- TNF inhibitors: 1.70x higher risk (95% CI: 1.09, 2.66).
Vaccine Performance and Demographics
The study found a notable difference in vaccine efficacy within this population. Recipients of the mRNA-1273 (Moderna) vaccine had a 34% lower risk of breakthrough infection compared to those who received BNT162b2 (Pfizer-BioNTech) (aHR 0.66, 95% CI: 0.50, 0.86).
Interestingly, older age was associated with a slightly lower risk of breakthrough infection (aHR 0.98 per year). This "age paradox" likely reflects behavioral differences, as older or more frail patients may have adhered more strictly to social distancing and masking protocols. Factors such as sex, BMI, race, and ethnicity showed no significant association with breakthrough risk.
Discussion
These findings confirm that the impaired antibody responses observed in lab settings have tangible clinical consequences. The high risk associated with B-cell depleting therapies (anti-CD20) and T-cell costimulation blockers (CTLA-4 Ig) suggests that these patients remain highly vulnerable even after a primary vaccine series.
Limitations
- The Omicron Factor: The study concluded just as the Omicron variant became dominant. Given Omicron's increased immune evasion, the specific hazard ratios may differ in the current landscape.
- Behavioral Confounders: EHR data cannot account for individual masking habits or social exposures. It is possible that patients on high-risk medications were more cautious, potentially leading to an underestimation of the true biological risk.
- Asymptomatic Cases: By relying on documented tests, the study likely missed mild or asymptomatic cases that did not prompt clinical interaction.
Conclusion
For patients with rheumatic diseases, the risk of COVID-19 breakthrough is heavily influenced by their specific medication regimen and vaccine type. These results underscore the necessity of additional mitigation strategies—including booster doses and potentially pre-exposure prophylaxis—for those on high-risk immunomodulators like Rituximab and Abatacept.
Summary updated